High levels of TNFα in patients with COVID-19 refractory to tocilizumab

Eur J Cancer. 2021 May:149:102-104. doi: 10.1016/j.ejca.2021.01.056. Epub 2021 Mar 20.

Authors

F X Danlos¹, F Ackermann², J Rohmer², M Roumier², A Marabelle³, J M Michot⁴

Affiliations

¹ INSERM U1015, Gustave Roussy Villejuif, France.
² Hôpital Foch, Suresnes, France.
³ INSERM U1015, Gustave Roussy Villejuif, France; Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France. Electronic address: [email protected].
⁴ Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Tumor Necrosis Factor-alpha

Substances

Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
tocilizumab